PMID- 24353411
OWN - NLM
STAT- MEDLINE
DCOM- 20140728
LR  - 20211021
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 8
DP  - 2013
TI  - Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: 
      findings from a single-center primary care cohort.
PG  - 613-9
LID - 10.2147/COPD.S53707 [doi]
AB  - BACKGROUND: Once-daily long-acting beta2-agonists (LABAs) are an important treatment 
      option, either alone or in combination with other inhaled long-acting 
      bronchodilators in the management of chronic obstructive pulmonary disease 
      (COPD). AIMS/OBJECTIVES: To audit the effectiveness of indacaterol as maintenance 
      therapy in patients with moderate-to-severe COPD (Global initiative for chronic 
      Obstructive Lung Disease [GOLD] stage II/III). METHODS: This was a single-center 
      audit of a primary care COPD cohort comprising all patients treated with 
      indacaterol following treatment escalation (as per National Institute for Health 
      and Care Excellence guidelines) or failure with other therapies. The sample was 
      restricted to patients treated for a minimum of 12 months with indacaterol, for 
      whom preswitching and follow-up spirometry as well as exacerbation frequency data 
      were available (GOLD spirometry guidelines). Pulmonary function was assessed by 
      spirometry (recorded as forced expiratory volume in 1 second [FEV1] expressed as 
      percentage predicted). Relevant self-reported qualitative information was 
      recorded in descriptive terms for quality of life (QoL) assessment. RESULTS: A 
      total of 15 patients met the audit inclusion criteria (66.6% male, mean age 
      64.9+/-7.7 years). COPD disease duration ranged from 1 to 22 years; 93% had GOLD 
      stage II or III COPD. Follow-up ranged in duration from 12 to 27 months. 
      Indacaterol was associated with a significant reduction in exacerbation frequency 
      compared with the 12 months prior to initiation (P=0.02). In those patients who 
      experienced three or more exacerbations/year, mean exacerbation rate fell from 
      5.43+/-1.07 to 2.43+/-0.2 after 12 months treatment with indacaterol (P=0.02). A 
      reduction in dyspnea was noted in 53% of patients. Similarly, improvements in 
      exercise tolerance and well-being were self-reported in 67% and 93%, 
      respectively. CONCLUSION: Indacaterol was found to be an effective LABA as an 
      escalation or switch medication in patients with moderate-to-severe COPD. 
      Indacaterol was effective both as monotherapy and in combination with a 
      long-acting muscarinic antagonist. Switching to indacaterol from a LABA/inhaled 
      corticosteroid fixed-combination inhaler significantly reduced the number of 
      acute exacerbations and also improved self-reported QoL.
FAU - Singh, Mukesh P
AU  - Singh MP
AD  - Horsefair Practice Group, Sandy Lane Health Centre, Rugeley, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131209
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Indans)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Quinolones)
RN  - 8OR09251MQ (indacaterol)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists/*therapeutic use
MH  - Aged
MH  - Bronchodilator Agents/*therapeutic use
MH  - Drug Substitution
MH  - Drug Therapy, Combination
MH  - Drug Utilization Review
MH  - Dyspnea/drug therapy/physiopathology
MH  - England
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Indans/*therapeutic use
MH  - Lung/*drug effects/physiopathology
MH  - Male
MH  - Medical Audit
MH  - Middle Aged
MH  - Muscarinic Antagonists/therapeutic use
MH  - *Primary Health Care
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology
MH  - Quality of Life
MH  - Quinolones/*therapeutic use
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC3862397
OTO - NOTNLM
OT  - audit
OT  - bronchodilators
OT  - chronic obstructive pulmonary disease
OT  - effectiveness
OT  - indacaterol
OT  - primary care
EDAT- 2013/12/20 06:00
MHDA- 2014/07/30 06:00
PMCR- 2013/12/09
CRDT- 2013/12/20 06:00
PHST- 2013/12/20 06:00 [entrez]
PHST- 2013/12/20 06:00 [pubmed]
PHST- 2014/07/30 06:00 [medline]
PHST- 2013/12/09 00:00 [pmc-release]
AID - copd-8-613 [pii]
AID - 10.2147/COPD.S53707 [doi]
PST - ppublish
SO  - Int J Chron Obstruct Pulmon Dis. 2013;8:613-9. doi: 10.2147/COPD.S53707. Epub 
      2013 Dec 9.